No abstract

No abstract

No abstract

This paper investigates the stability of equilibrium points in the restricted three-body problem, in which the masses of the luminous primaries vary isotropically in accordance with the unified Meshcherskii law, and their motion takes place within the framework of the GyldenMeshcherskii problem. For the autonomized system, it is found that collinear and coplanar points are unstable, while the triangular points are conditionally stable. It is also observed that, in the triangular case, the presence of a constant κ, of a particular integral of the Gylden-Meshcherskii problem, makes the destabilizing tendency of the radiation pressures strong. The stability of equilibrium points varying with time is tested using the Lyapunov Characteristic Numbers (LCN). It is seen that the range of stability or instability depends on the parameter κ. The motion around the equilibrium points L i (i = 1, 2, . . . , 7) for the restricted three-body problem with variable masses is in general unstable.

Development of an efficient and scalable process for the human immunodeficiency virus (HIV) protease inhibitor BMS-232632 1-[4-(pyridin-2-yl)phenyl]-5(S)-2,5-bis{[N-(methoxycarbonyl)-L-tert-leucinyl]-amino}-4(S)-hydroxy-6-phenyl-2-azahexane, is described. The key step in the synthesis of the intermediate N-1-(tert-butyloxycarbonyl)-N-2-[4-(pyridin-2-yl)benzylidene]hydrazone (11) was the Pd-mediated coupling of boronic acid 9 with 2-bromopyridine. An efficient procedure was developed for the chemoselective reduction of hydrazone 11 to hydrazine carbamate 4 (6) was prepared stereoselectively from chiral diol 10. The subsequent union of 4 and 6 followed by coupling with N-methoxycarbonyl-L-tert-leucine provided the free base BMS-232632 in high yield. Evaluation of a variety of salts and identification of bisulfate salt 19 with enhanced bioavailability are also described. . The key intermediate N-(tert-butyloxycarbonyl)-2(S)-amino-1-phenyl-3(R)-3,4-epoxy-butane